Please view the discount options for courses before registering here.
The Finance of Biotech focuses on various aspects of what’s needed for successful fundraising at each stage of company growth. The course addresses some of the common questions around risks of investing, types of investment securities, and differences between private and public markets. John Tagliamonte and Atul Deshpande, CEO’s of biotech startups, respectively, will lead the course with invited guest lecturers from venture capital, private equity, investment banks, and pharmaceutical companies.
- Tuesday, July 19th, 2022 10:30 AM – 1:00 PM EST
- Wednesday, July 20th, 2022 10:30 AM – 1:00 PM EST
- Friday, July 22nd, 2022 10:30 AM – 1:00 PM EST
- Primary Risks of Biotech Investing
- Starting with Debt and/or Stock Equity, Major Stages of Startup Financing
- Dilutive and Non-Dilutive Funding
- Assessing Your Company’s Value
- Common Types of Investment Securities
Chief Executive Officer, Mellitus
John Tagliamonte has more than 20 years of experience in executive leadership with responsibility for business development, finance, commercial and business operations, strategic planning, finance and legal functions with established and emerging public and private life sciences companies. As the first Entrepreneur-in-Residence with MassBio, he was responsible for forward-looking program content across the organization, while helping to develop the next generation of biotech entrepreneurs. He currently serves on the business advisory boards of therapeutic startups WntRx, Fractal, MarkTx, PhagePro and Tantu. Previously he led business development at Juniper, was Chief Business Officer of Oxyrane and held various executive business leadership roles at Anchor Therapeutics, ImmunoGen and Johnson & Johnson, as well as venture investing with Safeguard. He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad. Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.
Atul Deshpande, Ph.D., MBA
Chief Executive Officer, IMMEDIATE Therapeutics
Atul is the CEO of IMMEDIATE Therapeutics, a clinical stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS), the most common cause of death and morbidity across the world.
Before joining IMMEDIATE Therapeutics, Atul was the Chief Strategy Officer and Head, US Operations of Harbour BioMed (HBM). Atul was primarily responsible for building the company’s short- and long-term strategy and portfolio along with a robust execution plan. In addition, he is also accountable for the HBM’s operations in both the US and EU to maintain HBM’s footprint across these 2 very important markets, along with managing key alliances in these regions. In 2020, he contributed to raising 2 VC funding rounds and taking the company public in the HK stock exchange raising a total of $400M.
Before HBM, Atul served as the Global Operations Head for the Dupixent Franchise with Sanofi. He led the operations, including marketing, market access, supply chain, to launch Dupixent in 52 markets across the world for Atopic Dermatitis and in major markets for Asthma. Prior to this, he led the operations for Sanofi’s Immunology R&D portfolio and was also responsible for new product planning and in-licensing evaluations. He spent 3 years in China as the Head of Asia Pacific R&D strategy to bring the global portfolio to China with minimal drug lag. Before Sanofi, Atul worked as a management consultant for 9 years on projects across the value chain of pharma.
Atul holds a Ph.D. from UC Irvine in Neuroscience and a post-doc from UCLA.